8-K: ImmuCell Reports Record Sales for Q1 2025, Driven by Strong Demand

ImmuCell Corporation announced preliminary, unaudited sales results for Q1 2025, achieving an all-time quarterly sales record of $8.1 million, a 11% increase compared to Q1 2024.

Summary

• ImmuCell Corporation reported preliminary, unaudited sales results for the first quarter of 2025.
• The company achieved record quarterly sales of $8.1 million, an 11% increase compared to $7.3 million in Q1 2024.
• Sales for the six-month period ended March 31, 2025, reached $15.8 million, a 28% increase from $12.4 million in the prior year.
• Sales for the twelve-month period ended March 31, 2025, also hit a record of $27.3 million, up 28% from $21.3 million.
• The company's order backlog decreased to $4.0 million as of March 31, 2025, from $4.4 million as of December 31, 2024.
• Annualized sales during the three-month period ended March 31, 2025, were approximately 108% of the company's estimated full capacity of $30 million per year.
• Annualized sales during the six-month period ended March 31, 2025, were approximately 105% of the company's estimated full capacity of $30 million per year.
• The company is initiating Investigational Product use of Re-Tain to test market acceptance of the product through a controlled launch.
• The company made its Non-Administrative New Animal Drug Application (NADA) submission, that included its fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling during early January of 2025.
• Clearing inspectional observations at the facilities of the company's contract manufacturer is still the critical path constraint to NADA approval.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record sales and improved production. However, the existing backlog and regulatory hurdles temper the overall sentiment.

Positives

• The company achieved record quarterly, six-month, and twelve-month sales.
• Sales increased by 11% in Q1 2025 compared to Q1 2024.
• The order backlog decreased, indicating improved production output.
• The company is operating at or above its estimated full capacity.
• The company is initiating Investigational Product use of Re-Tain to test market acceptance of the product through a controlled launch.
• The company made its Non-Administrative New Animal Drug Application (NADA) submission, that included its fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling during early January of 2025.

Negatives

• The company still has a backlog of $4.0 million, indicating unmet customer demand.
• Clearing inspectional observations at the facilities of the company's contract manufacturer is still the critical path constraint to NADA approval.

Risks

• The company's ability to meet customer demand is constrained by its production capacity.
• The company's future performance depends on obtaining regulatory approval for its products.
• The company's performance is subject to risks related to supply chain disruptions, inflation, and rising interest rates.
• The company's performance is subject to risks related to international disputes (including Russia's invasion of Ukraine and unrest in the Middle East) on the world economy including inflation and the price and availability of grain and oil.

Future Outlook

The company expects to continue providing prompt, preliminary reports on product sales until further notice. The company is initiating Investigational Product use of Re-Tain to test market acceptance of the product through a controlled launch. This opportunity is not, however, expected to generate significant revenue or profit.

Management Comments

• Michael F. Brigham, President and CEO of ImmuCell, commented that the level of production output and sales achieved during the last six months demonstrates a strong improvement in performance compared to 2023 and the first nine months of 2024.
• Michael F. Brigham, President and CEO of ImmuCell, commented that any amount of backlog is too much because it means we are not fully meeting customer demand.

Industry Context

ImmuCell operates in the animal health industry, specifically focusing on products for dairy and beef cattle. The company's growth reflects increasing demand for solutions that improve animal health and productivity, particularly in the areas of mastitis treatment and newborn calf immunity.

Comparison to Industry Standards

• Without specific financial details from direct competitors, it's challenging to provide a precise comparison.
• However, companies like Zoetis and Elanco Animal Health are major players in the broader animal health market.
• ImmuCell's focus on niche products like First Defense and Re-Tain differentiates it from these larger companies, which offer a wider range of products.
• ImmuCell's revenue growth of 28% over the last twelve months is strong, suggesting that the company is gaining market share or benefiting from favorable industry trends.

Stakeholder Impact

• Shareholders will likely react positively to the record sales and growth.
• Employees may benefit from increased job security and potential bonuses.
• Customers may experience improved product availability as the company addresses the backlog.
• Suppliers may see increased demand for their products as the company expands production.

Next Steps

• The company plans to host a conference call on May 15, 2025, to discuss the unaudited financial results for the quarter ended March 31, 2025.
• The company will continue to pursue regulatory approval for Re-Tain.
• The company will continue to address the order backlog and increase production capacity.

Key Dates

Keywords

ImmuCell, sales results, animal health, dairy cattle, beef cattle, First Defense, Re-Tain, mastitis, NADA, production capacity